Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Sells $217,200.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 40,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the transaction, the insider now owns 1,353,510 shares in the company, valued at $7,349,559.30. This represents a 2.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $5.81 on Monday. The stock has a market capitalization of $894.39 million, a PE ratio of -12.91 and a beta of 2.32. The stock has a 50-day simple moving average of $3.88 and a 200 day simple moving average of $3.41. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.69 and a twelve month high of $5.92.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. NewEdge Advisors LLC bought a new position in Xeris Biopharma during the fourth quarter worth $34,000. R Squared Ltd acquired a new stake in Xeris Biopharma in the 4th quarter worth $42,000. Quantbot Technologies LP acquired a new stake in Xeris Biopharma in the 3rd quarter worth $44,000. Cibc World Markets Corp acquired a new position in shares of Xeris Biopharma during the fourth quarter valued at about $44,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Xeris Biopharma in the fourth quarter valued at about $45,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

XERS has been the subject of several recent research reports. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Craig Hallum increased their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday, March 7th. Piper Sandler reissued a “neutral” rating and issued a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Leerink Partners lifted their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $5.92.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.